Details of the Drug
General Information of Drug (ID: DMGXPJV)
Drug Name |
3-(4,5-Bis-biphenyl-4-yl-1H-imidazol-2-yl)-phenol
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
3-(4,5-Bis-biphenyl-4-yl-1H-imidazol-2-yl)-phenol; 296792-52-4; CHEMBL443007; 3-[4,5-bis(4-phenylphenyl)-1H-imidazol-2-yl]phenol; AC1M4HYZ; AC1Q790A; CTK8A0066; MolPort-001-732-645; ZINC6028400; BDBM50113297; STK758717; AKOS001063669; NE26785; MCULE-4347250395; UPCMLD0ENAT5224754:001; ST4040901; KB-335272; EN300-07381; 3-[4,5-bis(4-phenylphenyl)imidazol-2-yl]phenol; SR-01000521283; J-510645; SR-01000521283-1; Z56935326; 3-[4,5-di(biphenyl-4-yl)-1H-imidazol-2-yl]phenol; 3-(4,5-bis-biphenyl-4-yl-1h-imidazol-2-yl)phenol
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 1 | Molecular Weight (mw) | 464.6 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 7.9 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 5 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 2 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 2 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||